A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder

Eric Hollander, Lorrin M. Koran, Wayne K. Goodman, John H. Greist, Philip T. Ninan, Haichen Yang, David Li, Luigi M. Barbato

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Objective: The aim of this 12-week, double-blind, flexible-dose, placebo-controlled, parallelarm, multicenter trial was to determine the safety and efficacy of fluvoxamine in a controlled-release (CR) formulation in adult outpatients with obsessive-compulsive disorder (OCD). Method: 253 adult outpatients with DSM-IV OCD were randomly assigned to receive 100 to 300 mg of fluvoxamine CR (N = 127) or placebo (N = 126) once daily for 12 weeks. Intent-to-treat analyses of efficacy assessments with the Yale-Brown Obsessive Compulsive Scale (YBOCS), Clinical Global Impressions-Severity of Illness scale (CGI-S), and Clinical Global Impressions-Improvement scale (CGI-I) were conducted. Results: Fluvoxamine CR was significantly (p < .05) superior to placebo in decreasing YBOCS total score beginning at week 2. This early response was sustained at all subsequent visits. At endpoint, there was a mean decrease of 8.5 ± 0.7 (31.7%) in the YBOCS total score compared with baseline in the fluvoxamine CR treatment group versus a mean decrease of 5.6 ± 0.7 (21.2%) in the placebo group (p =.001). Fluvoxamine CR was also significantly superior to placebo in lowering the severity of illness (CGI-S, p = .002) and in producing clinical improvement (CGI-I, p <.01). At endpoint, significantly greater percentages of the fluvoxamine CR treatment group were responders (p = .002) and remitters (p = .019) compared with the placebo group. Conclusion: Over 12 weeks, fluvoxamine CR treatment was associated with a statistically significant and clinically relevant reduction in OCD severity and was found to be safe and well tolerated. The early onset of therapeutic effect, starting from week 2, was of particular interest.

Original languageEnglish (US)
Pages (from-to)640-647
Number of pages8
JournalJournal of Clinical Psychiatry
Volume64
Issue number6
StatePublished - Jun 1 2003
Externally publishedYes

Fingerprint

Fluvoxamine
Obsessive-Compulsive Disorder
Placebos
Safety
Outpatients
Therapeutic Uses
Diagnostic and Statistical Manual of Mental Disorders
Multicenter Studies
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. / Hollander, Eric; Koran, Lorrin M.; Goodman, Wayne K.; Greist, John H.; Ninan, Philip T.; Yang, Haichen; Li, David; Barbato, Luigi M.

In: Journal of Clinical Psychiatry, Vol. 64, No. 6, 01.06.2003, p. 640-647.

Research output: Contribution to journalArticle

Hollander, Eric ; Koran, Lorrin M. ; Goodman, Wayne K. ; Greist, John H. ; Ninan, Philip T. ; Yang, Haichen ; Li, David ; Barbato, Luigi M. / A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. In: Journal of Clinical Psychiatry. 2003 ; Vol. 64, No. 6. pp. 640-647.
@article{32e15c2bac744933b8da60728c8aa65a,
title = "A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder",
abstract = "Objective: The aim of this 12-week, double-blind, flexible-dose, placebo-controlled, parallelarm, multicenter trial was to determine the safety and efficacy of fluvoxamine in a controlled-release (CR) formulation in adult outpatients with obsessive-compulsive disorder (OCD). Method: 253 adult outpatients with DSM-IV OCD were randomly assigned to receive 100 to 300 mg of fluvoxamine CR (N = 127) or placebo (N = 126) once daily for 12 weeks. Intent-to-treat analyses of efficacy assessments with the Yale-Brown Obsessive Compulsive Scale (YBOCS), Clinical Global Impressions-Severity of Illness scale (CGI-S), and Clinical Global Impressions-Improvement scale (CGI-I) were conducted. Results: Fluvoxamine CR was significantly (p < .05) superior to placebo in decreasing YBOCS total score beginning at week 2. This early response was sustained at all subsequent visits. At endpoint, there was a mean decrease of 8.5 ± 0.7 (31.7{\%}) in the YBOCS total score compared with baseline in the fluvoxamine CR treatment group versus a mean decrease of 5.6 ± 0.7 (21.2{\%}) in the placebo group (p =.001). Fluvoxamine CR was also significantly superior to placebo in lowering the severity of illness (CGI-S, p = .002) and in producing clinical improvement (CGI-I, p <.01). At endpoint, significantly greater percentages of the fluvoxamine CR treatment group were responders (p = .002) and remitters (p = .019) compared with the placebo group. Conclusion: Over 12 weeks, fluvoxamine CR treatment was associated with a statistically significant and clinically relevant reduction in OCD severity and was found to be safe and well tolerated. The early onset of therapeutic effect, starting from week 2, was of particular interest.",
author = "Eric Hollander and Koran, {Lorrin M.} and Goodman, {Wayne K.} and Greist, {John H.} and Ninan, {Philip T.} and Haichen Yang and David Li and Barbato, {Luigi M.}",
year = "2003",
month = "6",
day = "1",
language = "English (US)",
volume = "64",
pages = "640--647",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "6",

}

TY - JOUR

T1 - A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder

AU - Hollander, Eric

AU - Koran, Lorrin M.

AU - Goodman, Wayne K.

AU - Greist, John H.

AU - Ninan, Philip T.

AU - Yang, Haichen

AU - Li, David

AU - Barbato, Luigi M.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Objective: The aim of this 12-week, double-blind, flexible-dose, placebo-controlled, parallelarm, multicenter trial was to determine the safety and efficacy of fluvoxamine in a controlled-release (CR) formulation in adult outpatients with obsessive-compulsive disorder (OCD). Method: 253 adult outpatients with DSM-IV OCD were randomly assigned to receive 100 to 300 mg of fluvoxamine CR (N = 127) or placebo (N = 126) once daily for 12 weeks. Intent-to-treat analyses of efficacy assessments with the Yale-Brown Obsessive Compulsive Scale (YBOCS), Clinical Global Impressions-Severity of Illness scale (CGI-S), and Clinical Global Impressions-Improvement scale (CGI-I) were conducted. Results: Fluvoxamine CR was significantly (p < .05) superior to placebo in decreasing YBOCS total score beginning at week 2. This early response was sustained at all subsequent visits. At endpoint, there was a mean decrease of 8.5 ± 0.7 (31.7%) in the YBOCS total score compared with baseline in the fluvoxamine CR treatment group versus a mean decrease of 5.6 ± 0.7 (21.2%) in the placebo group (p =.001). Fluvoxamine CR was also significantly superior to placebo in lowering the severity of illness (CGI-S, p = .002) and in producing clinical improvement (CGI-I, p <.01). At endpoint, significantly greater percentages of the fluvoxamine CR treatment group were responders (p = .002) and remitters (p = .019) compared with the placebo group. Conclusion: Over 12 weeks, fluvoxamine CR treatment was associated with a statistically significant and clinically relevant reduction in OCD severity and was found to be safe and well tolerated. The early onset of therapeutic effect, starting from week 2, was of particular interest.

AB - Objective: The aim of this 12-week, double-blind, flexible-dose, placebo-controlled, parallelarm, multicenter trial was to determine the safety and efficacy of fluvoxamine in a controlled-release (CR) formulation in adult outpatients with obsessive-compulsive disorder (OCD). Method: 253 adult outpatients with DSM-IV OCD were randomly assigned to receive 100 to 300 mg of fluvoxamine CR (N = 127) or placebo (N = 126) once daily for 12 weeks. Intent-to-treat analyses of efficacy assessments with the Yale-Brown Obsessive Compulsive Scale (YBOCS), Clinical Global Impressions-Severity of Illness scale (CGI-S), and Clinical Global Impressions-Improvement scale (CGI-I) were conducted. Results: Fluvoxamine CR was significantly (p < .05) superior to placebo in decreasing YBOCS total score beginning at week 2. This early response was sustained at all subsequent visits. At endpoint, there was a mean decrease of 8.5 ± 0.7 (31.7%) in the YBOCS total score compared with baseline in the fluvoxamine CR treatment group versus a mean decrease of 5.6 ± 0.7 (21.2%) in the placebo group (p =.001). Fluvoxamine CR was also significantly superior to placebo in lowering the severity of illness (CGI-S, p = .002) and in producing clinical improvement (CGI-I, p <.01). At endpoint, significantly greater percentages of the fluvoxamine CR treatment group were responders (p = .002) and remitters (p = .019) compared with the placebo group. Conclusion: Over 12 weeks, fluvoxamine CR treatment was associated with a statistically significant and clinically relevant reduction in OCD severity and was found to be safe and well tolerated. The early onset of therapeutic effect, starting from week 2, was of particular interest.

UR - http://www.scopus.com/inward/record.url?scp=0037929415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037929415&partnerID=8YFLogxK

M3 - Article

C2 - 12823077

AN - SCOPUS:0037929415

VL - 64

SP - 640

EP - 647

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 6

ER -